Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060930 | 0.86 | BRAF (0.67) | BRAFKDR | |
| SCHEMBL13884181 | 0.86 | BRAF (0.77) | BRAFKDR | |
| SCHEMBL13097080 | 0.85 | BRAF (0.66) | BRAFKDR | |
| SCHEMBL3062223 | 0.84 | BRAF (0.65) | BRAFKDR | |
| SCHEMBL3058197 | 0.83 | BRAF (0.64) | BRAFKDR | |
| SCHEMBL3061878 | 0.82 | BRAF (0.63) | BRAFKDR | |
| SCHEMBL3427318 | 0.81 | BRAF (0.79) | BRAFKDR | |
| SCHEMBL3061583 | 0.81 | BRAF (0.61) | BRAFKDR | |
| SCHEMBL3426197 | 0.81 | BRAF (1.00) | BRAF | |
| SCHEMBL3060699 | 0.81 | BRAF (0.69) | BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691866-B2 | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317359-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | RAF1, BRAF, ARAF | BRAF 2/4885KDR 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.